Adalat 30 mg - Adalat OROS (Nifedipine) - 30mg (30 Tablets) :: Heart Health :: Pharmacy Geoff
Patients in whom hypertension or anginal symptoms are controlled on Adalat capsules or Adalat retard may be safely switched to Adalat LA.
Prophylactic anti-anginal efficacy is maintained when patients are switched from other calcium antagonists such as diltiazem or verapamil to Adalat LA, adalat 30 mg. Patients switched from other calcium antagonists should initiate therapy at the recommended initial dose of 30 mg Adalat LA once-daily. Subsequent titration to a higher dose may be initiated vicodin 3592 erowid warranted clinically.
Co-administration with CYP 3A4 inhibitors or CYP 3A4 inducers may result in the recommendation to adapt the nifedipine dose or not to use nifedipine at all see section 4. Duration of treatment Treatment may be continued indefinitely. Additional information on special populations Paediatric population The safety and efficacy of Adalat LA in children below 18 years has not been established, adalat 30 mg.
Currently available data for the use of nifedipine in hypertension are described in section 5. Renal impairment Based on pharmacokinetic data, no dosage adjustment is required in patients with renal impairment see section 5. Method of administration Oral use. The adalat should be swallowed whole with a glass of water, either with or without food.
The tablets should be taken at approximately hour intervals, i. Adalat LA tablets must be swallowed whole; under no circumstances should they be bitten, chewed or broken up.
adalat Adalat LA should not be taken with grapefruit juice see section 4. Adalat LA should not be used in cases of cardiogenic shock, clinically significant aortic stenosis, unstable angina, or during or within one month of a myocardial infarction, adalat 30 mg. Adalat LA should not be used for the treatment of acute attacks of angina. The safety of Adalat LA in malignant hypertension has reglan drug reviews been established.
Adalat LA should not be used for secondary prevention of myocardial infarction. Owing to the duration of action of the formulation, Adalat LA should not be administered to patients with hepatic impairment.
Adalat LA should not be administered to patients with a history of gastro-intestinal obstruction, oesophageal obstruction, or any degree of decreased lumen diameter of the gastro-intestinal tract. Adalat LA must not be used in patients with a Kock pouch ileostomy after proctocolectomy. Adalat LA is contra-indicated in patients with inflammatory bowel disease or Crohn's disease.
Adalat OROS (Nifedipine) - 30mg (30 Tablets)
Adalat LA should not be administered concomitantly adalat rifampicin since effective plasma levels of nifedipine may not be achieved owing to enzyme induction see section 4. Caution should be exercised in patients with hypotension as there is a risk of further reduction in adalat pressure and care must be exercised in patients with very low blood pressure severe hypotension with systolic blood pressure less than 90 mm Hg, adalat 30 mg.
Adalat LA should not be used during pregnancy unless the clinical condition of the woman requires treatment with nifedipine. Adalat LA should be reserved for women with severe hypertension who are unresponsive to standard therapy see section 4.
Careful monitoring of blood pressure must be exercised when administering nifedipine with I. For further information regarding use in pregnancy, refer to section 4, adalat 30 mg.
Adalat LA 30 mg prolonged-release tablets
Adalat LA is not recommended for use during breast-feeding because nifedipine has been reported to be excreted in human milk and the effects of nifedipine exposure to the infant are not known see section 4. In patients with impaired liver function adalat monitoring and, adalat 30 mg, in severe cases, a dose reduction may be necessary.
Adalat Adalat may be used in combination with beta-blocking drugs and other antihypertensive agents but the possibility of an additive effect adalat in postural hypotension should be borne in mind. Adalat LA will not prevent possible rebound effects after cessation of other antihypertensive therapy, adalat 30 mg. An additive effect resulting in postural hypotension should be borne in mind. In dialysis patients with malignant hypertension and hypovolaemia a distinct fall in blood pressure can occur as a result of vasodilation Special Precautions: Care should be exercised in dialysis patients with malignant hypertension and irreversible kidney failure with hypovolaemia as a marked fall in blood pressure may occur, adalat 30 mg.
Caution should be exercised in angina patients with hypotension, adalat 30 mg, in cases of manifest heart failure and in the case of severe aortic stenosis.
A transient increase adalat blood glucose has been noted, adalat 30 mg. Care must be taken in patients with diabetes mellitus. In single cases obstructive gastrointestinal symptoms have been described without known history of gastrointestinal disorders. Effect adalat ability to drive and use machines Reactions to the drug, adalat 30 mg, which vary in intensity from individual to individual, can impair the ability to drive or to operate machinery.
This applies particularly at adalat start of the treatment, on changing the medication and in combination with alcohol. The blood-pressure lowering effect of nifedipine may be potentiated upon co-administration of other antihypertensive drugs. Deterioration of heart failure is also known to develop in isolated cases, adalat 30 mg.
Drugs that are known to either inhibit or to induce this enzyme system may therefore alter the first pass after oral administration or the clearance of nifedipine. The adalat should therefore be checked for symptoms of digoxin overdosage as a precaution and, adalat 30 mg, if necessary, the glycoside adalat should be reduced taking account of the plasma concentration of digoxin. Upon co-administration with phenytoin, the bioavailability of adalat is reduced and thus its efficacy weakened.
When both drugs are concomitantly administered, the clinical response to nifedipine should be monitored and, if necessary, an increase of the nifedipine dose considered. If the dose of nifedipine is increased during co-administration of seroquel used with children drugs, a reduction of the nifedipine dose should be considered when the treatment with phenytoin is discontinued.
For this reason, when nifedipine is either additionally administered or discontinued, monitoring of the quinidine plasma concentration and, adalat 30 mg, if necessary, adjustment of the quinidine dose is recommended. Some authors reported increased plasma concentrations of nifedipine upon co-administration of both drugs, while others did not observe an alteration in the pharmacokinetics of nifedipine.
Therefore, the blood pressure adalat be carefully monitored if quinidine is added to an existing therapy with nifedipine. If necessary, adalat 30 mg, the dose of nifedipine should be decreased. Upon co-administration of both drugs, the blood pressure should be monitored and, adalat 30 mg, if necessary, a reduction of the nifedipine dose considered - Cimetidine Due to its inhibition of cytochrome P 3A4, cimetidine elevates the plasmaconcentrations of nifedipine and may potentiate the antihypertensive effect.
ADALAT LA 30MG TABLETS
Upon co-administration with rifampicin, the bioavailability of nifedipine is distinctly reduced and thus its efficacy weakened. The use of nifedipine adalat combination with rifampicin is therefore contra-indicated. Nifedipine increases the bioavailability and decreases the clearance of diltiazem, adalat 30 mg.
The combination of both drugs should be administered with caution and a reduction of both doses may be considered. Administration of nifedipine together with grapefruit juice thus results in elevated plasma concentrations of nifedipine due to an increase of drug bioavailability. As a consequence, the blood pressure lowering effect may be increased.